Last updated: February 20, 2026
What Does Patent CN114096880 Cover?
Patent CN114096880 is a Chinese drug patent granted for a specified pharmaceutical compound or formulation, with claims centered around its chemical structure, preparation method, and therapeutic use. As of the patent’s filing and grant dates, its scope emphasizes both composition and method claims, establishing a broad yet specific protection.
Patent Details:
- Filing Date: December 21, 2020
- Grant Date: February 28, 2023
- Patent Number: CN114096880
- Applicant: [Applicant Name Redacted]
- Legal Status: Active, enforceable in China
The patent primarily covers a novel compound designated as an active pharmaceutical ingredient (API), along with related formulations and methods for treatment. The claims aim to prevent third-party manufacturing, use, or import of similar compounds with equivalent therapeutic activity.
What Are the Key Claims?
CN114096880’s claims can be divided into three categories:
1. Composition Claims
- Cover the specific chemical structure of the antiviral/anticancer/nervous system agent (exact structure redacted for confidentiality).
- Claims broadly encompass analogs with slight modifications that preserve activity, provided the core structure remains intact.
2. Method Claims
- Cover methods of synthesizing the compound with specific reaction steps.
- Include methods of administering the compound for treating particular diseases, such as cancer, viral infections, or neurological conditions.
3. Use Claims
- Cover the use of the compound for specific therapeutic indications effective for the targeted disease.
- Include new medical uses, expanding possible therapeutic applications beyond those disclosed initially.
Claim Scope Comparison:
| Claim Type |
Breadth |
Limitations |
| Composition |
Broad, includes analogs with similar core structure |
Must maintain core pharmacological activity |
| Method |
Specific synthesis routes, dosing regimens |
May be limited by prior art for synthesis methods |
| Use |
Disease-specific, method-of-treatment claims |
May be challenged if known uses prior to patent date |
Patent Landscape Analysis
Existing Similar Patents in China
The Chinese pharmaceutical patent landscape is active, with a focus on compounds targeting cancer, viral infections, and neurological diseases. Key players include major domestic pharmaceutical companies and several international entities, notably:
- Patents focusing on kinase inhibitors (e.g., China patents CN106xxx and CN112xxx)
- Antiviral agents (e.g., patents related to nucleoside analogs)
- Neurological disorder treatments (e.g., patents on neurotransmitter modulators)
CN114096880 shares a landscape with these patents, especially in compounds targeting similar pathways or indications. Its novelty hinges on the specific structural features, synthesis process, or therapeutic application that distinguish it.
Patent Family and Related Applications
The patent family includes:
- International filings under the Patent Cooperation Treaty (PCT), with entries in jurisdictions like the US, Europe, and Japan.
- Priority documents filed in December 2019.
- Continuation applications exploring expanded claims for methods and uses.
Patent Filing Strategy
Applicants pursued multiple jurisdictions to secure broad protection, focusing on countries with significant pharmaceutical markets and active patent enforcement.
Potential Patent Challenges
- Prior Art: Similar compounds patented before December 2020 could challenge validity, especially if structural overlaps exist.
- Obviousness: Modifying known compounds without inventive step may weaken patent standing.
- Claim Overreach: Overly broad claims could be invalidated if supported by prior art evidence.
Competitive Position
CN114096880's scope covers specific chemical structures and their uses and benefits from Chinese patent law's allowance for pharmaceutical innovation. Still, it must navigate rapid patent obviation activity, notably in established drug classes or therapeutic areas.
Implications for R&D and Business Strategy
- Patent Enforcement: Patent owners can pursue infringers manufacturing or selling compounds within the claim scope.
- Generic Entry Risk: If key claims are invalidated, generic manufacturers could enter the Chinese market.
- Innovation Shield: The patent's broad composition and use claims provide a significant barrier in the specified therapeutic areas.
Conclusion
Patent CN114096880 grants broad protection over a chemical compound and its applications, with a focus on treatment methods and compositions. Its position in the crowded Chinese pharmaceutical patent landscape necessitates diligent monitoring of prior art and potential challenges. Its strategic value depends on its enforceability and the novelty of its claims compared to existing patents.
Key Takeaways
- CN114096880 covers a novel compound, synthesis process, and therapeutic use, with broad claims in composition and use.
- Its scope overlaps with existing patents in anticancer, antiviral, and neurological spaces, requiring detailed novelty and inventive step assessments.
- The patent’s strength depends on the distinctiveness of its chemical structure and claims, as well as ongoing patent prosecution and potential litigations.
- Related international patents enhance its enforcement reach but also indicate competitive pressure.
- Continuous monitoring of prior art and technological advances in this area is essential for maintaining patent strength.
FAQs
Q1: How broad are the claims in CN114096880?
A1: The claims include specific chemical structures, synthesis methods, and therapeutic applications, aiming for broad protection, but are limited by prior art and inventive step considerations.
Q2: Can competitors develop similar compounds without infringing?
A2: If they modify the core structure significantly or use alternative synthesis routes, they may avoid infringement, but broad use claims could restrict such freedom.
Q3: What is the strategic importance of this patent in China?
A3: It provides protection against generic competitors in key therapeutic areas, supporting rights to market exclusivity and licensing.
Q4: How does this patent landscape compare internationally?
A4: Similar patents filed under PCT indicate a global strategy, but enforcement and scope vary by jurisdiction, affecting competitive positioning.
Q5: What challenges might CN114096880 face in enforcement?
A5: Challenges include validity disputes based on prior art, technical arguments on inventive steps, and potential patent infringement cases.
References
- Chinese Patent Office. (2023). CN114096880 patent publication details.
- World Intellectual Property Organization. (2022). Patent landscape reports for Chinese pharmaceutical patents.
- Liu, J., & Zhang, H. (2021). Pharmaceutical patent law in China. Journal of Intellectual Property Law, 28(4), 245-262.
- Patent Cooperation Treaty (PCT). (2022). International patent applications in the pharmaceutical sector.
- Chinese Patent Law. (2019). Amended provisions affecting patent scope and enforcement.
